All In Biotech

Drug Trial Radar · NCT07922096

A First-in-human Study of SMP-656 in Subjects With Locally Advanced/ Metastatic HER2 Expressing or Mutated Solid Tumors

A Phase I, Two-Part, Open-Label, Multicenter Study of SMP-656 in Subjects With Locally Advanced/Metastatic HER2 Expressing or HER2-Mutated Solid Tumors to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor.

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Feb 1, 2024

Primary completion

Apr 30, 2026

Study completion Apr 30, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, first-in-human (FIH), phase 1 dose-escalation and cohort expansion study of SMP-656 in subjects with locally advanced/metastatic HER2 expressing or HER2-mutated solid tumors. The study consists of 2 parts: dose-escalation (Part 1) and cohort expansion (Part 2). Part 1 consists of dose escalation cohorts for determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Part 2 consists of expansion cohorts, including but not limited to breast cancer, non-small cell lung cancer, gynecologic, gastrointestinal and other solid tumors. A total of 35 participants were enrolled between February 2024 and April 2026. The trial has been completed.

Conditions

  • HER2-Expressing Advanced Solid Tumors
  • HER2-Mutated Advanced Solid Tumors
  • Metastatic Solid Tumors

Interventions

  • SMP-656 InjectionDrug

    SMP-656 was supplied as a 50 mg/vial injection for intravenous infusion and given Q3W at 0.5, 1.0, 1.5, 2.0, 2.5 or 3.0 mg/kg during dose escalation and at the selected dose level(s) during dose expansion. Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death or trial termination.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicity (DLT)Time frame: 21 days after the first dose of SMP-656
  2. Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D)Time frame: Through study completion, up to 27 months from first dose

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.